关闭
 
读者在线:用户名 密码
首页 期刊简介 投稿须知 期刊目录 专家风采 编委会 特邀顾问 联系我们 移动出版
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5



刊物信息

期刊名称:药物分析杂志
主管单位:中国科学技术协会
主办单位:中国药学会
承办:中国食品药品检定研究院
主编:金少鸿
地址:北京天坛西里2号
邮政编码:100050
电话:010-67012819,67058427
电子邮箱:ywfx@nicpbp.org.cn
国际标准刊号:ISSN 0254-1793
国内统一刊号:CN 11-2224/R
邮发代号:2-237
 

访问统计
您是第  3 0 8 2 2 5 5 位浏览者
您当前的位置:首页 >> 正文

重组人C1酯酶抑制剂中rcc-rhC1INH和ox-rhC1INH含量检测

Determination of rcc-rhC1INH and ox-rhC1INH in the recombinant human C1 esterase inhibitor

作者(英文):
分类号:R917
出版年·卷·期(页码):2018,38 (11):1911-1916
DOI: 10.16155/j.0254-1793.2017.01.01
-----摘要:-------------------------------------------------------------------------------------------

目的:分析重组人C1酯酶抑制剂(rhC1INH)中相关蛋白rcc-rhC1INH和ox-rhC1INH的含量。方法:采用反相高效液相色谱法进行测定,对该方法进行专属性、准确性和精密度检验,并用该方法对4批样品中的相关蛋白进行检测。结果:低浓度下,rhC1INH对照品、rcc-rhC1INH对照品和ox-rhC1INH对照品能够较好分离。rcc-rhC1INH和ox-rhC1INH 2种对照品质量浓度为0.2、1和1.4 mg·mL-1时的回收率均在85%~115%的范围内。对同1批3个待测样品进行测定,rcc-rhC1INH含量为(0.082±0.008)%,RSD为9.8%;ox-rhC1INH含量为(0.35±0.05)%,RSD为14.3%,显示该方法具有较好的专属性、准确性和精密度。4批测试样品中,rcc-rhC1INH的含量分别为0.083%、0.021%、0.033%、0.042%,ox-rhC1INH的含量分别为0.34%、0、0、0。结论:经方法学验证,RP-HPLC方法可用于rhC1INH中rcc-rhC1INH和ox-rhC1INH的含量检测。

-----英文摘要:---------------------------------------------------------------------------------------

Objective: To analyze the contents of related proteins rcc-C1INH and ox-C1INH in the recombinant human C1 esterase inhibitor(rhC1INH). Methods: The reversed phase high-performance liquid chromatography (RP-HPLC) was used to determine the relative proteins,the test was verified in specificity,accuracy and precision,and was used to detect the rcc-C1INH and ox-C1INH in 4 batches of samples. Results: RhC1INH reference,rcc-rhC1INH reference and ox-rhC1INH reference could be well separated under the low concentrations. The recovery rates for the reference substances of rcc-C1INH and ox-C1INH at three concentrations (0.2,1 and 1.4 mg·mL-1) were all in the range of 85%~115%. Three groups from one batch were determined separately,the contents of rcc-C1INH were (0.082±0.008)%,and the contents of ox-C1INH were (0.35±0.05)%,with RSDs of 9.8% and 14.3%,respectively. This method showed good results in specificity,accuracy and precision. Four batches of rhC1INH were determined,the contents of rcc-C1INH were 0.083%,0.021%,0.033% and 0.042% for each,and ox-C1INH were 0.34%,0,0,and 0,respectively. Conclusion: RP-HPLC can be used for the content determination of rcc-rhC1INH and ox-rhC1INH in rhC1INH.

-----参考文献:---------------------------------------------------------------------------------------
[1] RATNOFF OD,LEPOW IH.Some properties of an esterase derived from preparations of the first component of complement[J].J Exp Med,1957,106(2):327
[2] ZEERLEDER S.C1-inhibitor:more than a serine protease inhibitor[J].Semin Thromb Hemost,2011,37(4):362
[3] CRUZ MP.Conestat alfa(ruconest):first recombinant Cl esterase inhibitor for the treatment of acute attacks in patients with hereditary angioedema[J].P&T,2015,40(2):109
[4] BEINROHR L,HARMAT V,DOBO J,et al.C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and eonformational disease[J].J Biol Chem,2007,282(29):21100
[5] WAGENAAR-BOS IG,HACK CE.Structure and function of C1-inhibitor[J].Immunol Allergy Clin North Am,2006,26(4):615
[6] JOSEPH K,THOLANIKUNNEL BG,KAPLAN AP,et a1.Factor Ⅻ-independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor[J].J Allergy Clin Immunol,2009,124(1):143
[7] CALIEZI C,WUILLEMIN WA,ZEERLEDER S,et a1.C1-esterase inhibitor:an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema[J].Pharmacol Rev,2000,52(1):91
[8] BORK K,STEFFENSEN I,MACHNIG T.Treatment with C1-esterase inhibitor concentrate in type I or Ⅱ hereditary angioedema:a systematic literature review[J].Allergy Asthma Proc,2013,34(4):312
[9] 汪菲菲,李策生.人C1酯酶抑制剂的研究进展[J].中国生物制品学杂志,2017,30(11):1227 WANG FF,LI CS.Progress in research on C1 esterase inhibitor[J].Chin J Biologicals,2017,30(11):1227
[10] 陶蔚孙,李惟,姜涌明.蛋白质的分子基础[M].北京:高等教育出版社,2002:276 TAO YS,LI W,JIANG YM.The Molecular Basis of Protein[M].Beijing:Higher Education Press,2002:276
[11] 中华人民共和国药典2015年版.三部[S].2015:37,41 ChP 2015.Vol Ⅲ[S].2015:37,41
[12] 史新昌,杨靖清,韩春梅,等.N-末端氨基酸测序数据估计N-末端不均一的单链重组蛋白制品主肽链比例方法的建立[J].中国生物制品学杂志,2016,29(10):1073 SHI XC,YANG JQ,HAN CM,et al.Estimation of most-peptide-chain-component-ratio of heterogeneous N-terminal single chain recombinant protein by N-terminal sequencer data[J].Chin J Biol,2016,29(10):1073
[13] 陶磊,李响,周勇,等.我国已上市重组人促红细胞生成素的一级结构比较[J].中国药学杂志,2016,51(13):1071 TAO L,LI X,ZHOU Y,et al.Comparison of primary structure of recombinant human erythropoietin marketed in China[J].Chin Pharm J,2016,51(13):1071
[14] 陶磊,丁有学,刘兰,等.应用串联质谱技术分析几种重组蛋白药物的翻译后修饰[J].中国药学杂志,2015,50(19):1726 TAO L,DING YX,LIU L,et al.Indentification of several kinds of post-translational modifications in recombinant protein pharmaceuticals using MS/MS[J].Chin Pharm J,2015,50(19):1726
[15] 丁有学,韩春梅,毕华,等.SEC-HPLC法测定rhTNK-tPA单链含量[J].药物分析杂志,2014,34(7):1208 DING YX,HAN CM,BI H,et al.SEC-HPLC chromatography method for determination of rhTNK-tPA's single-chain content[J].Chin J Pharm Anal,2014,34(7):1208
[16] 毕华,韩春梅,丁有学,等.重组人血管内皮生长因子抑制剂中异天门冬氨酸含量检测[J].药物分析杂志,2015,35(5):879 BI H,HAN CM,DING YX,et al.Determination of isoaspartic acid in the recombinant human vascular endothelial growth factor inhibitor[J].Chin J Pharm Anal,2015,35(5):879

欢迎阅读《药物分析杂志》!您是该文第 30位读者!

药物分析杂志 © 2009
地址:北京天坛西里2号
邮政编码:100050; 技术支持:010-60213898

电子邮件:ywfx@nicpbp.org.cn